Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34988692/
Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host disease (GVHD) and the efficacy of...
Conclusion/Relevance: Our results indicated the substantial risk of acute GVHD after haploidentical DLI with CD3 cell count of 5.0×105/kg or higher and the favorable outcomes after preemptive DLI.
HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34970261/
The HLA-DRB3/4/5 loci are closely linked to the HLA-DRB1 gene. Mismatches in these loci occur with a frequency of about 8%-12% in otherwise 10/10 HLA-matched transplant pairs. There is preliminary...
Conclusion/Relevance: Our study results suggest that mismatches within the ARD of HLA-DRB3/4/5 genes significantly impact the outcome of otherwise fully matched uHSCT and support their consideration upon donor selection in the future.
Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review
Source : https://www.sciencedirect.com/science/article/abs/pii/S096632742100160X?via=ihub
Acute polymyositis is a rare manifestation of chronic graft vs host disease. * Usually presents with myalgia, proximal muscle weakness and high creatine kinase. * Biopsy shows perimysial inflammation and...
/>
Conclusion/Relevance: We present a case series of three patients who presented with APM as a sole presentation of cGvHD and were treated successfully with corticosteroids and ruxolitinib. We also conducted a systematic review including 72 patients to summarize current literature regarding APM associated with cGvHD after allo-HSCT.
Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
Source : https://www.tandfonline.com/doi/full/10.1080/16078454.2021.2009645
ABSTRACT Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative...
Conclusion: Based on new data and clinical experience, the panel of experts discussed ruxolitinib treatment in Belgian myelofibrosis patients with a focus on dose optimization/monitoring, adverse events, and interruption/rechallenge management.
Cytokine autoantibodies are stable throughout the haematopoietic stem cell transplantation course and are associated with distinct biomarker and blood cell profiles - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34907183/
1 Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. [email protected]. 2 Department of Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 3 Department of Clinical Immunology, Rigshospitalet, University of...
Conclusion: In this first study of c-aAbs in HSCT patients, we demonstrated that high-titre levels of c-aAb may both persist and emerge in patients over the course of HSCT and may be associated with altered immune biomarkers and cell profiles.